The Biotech Industry in 2020: Biotechnology in the time of pandemic.
by SMEBOOK (admin) · January 18, 2021
The innovative biotech industry relies on the smooth flow of risk capital to support the billion dollar road from the idea to approval and clinical benefit. Few other metric drive valuation. The most crucial is if these is the constant change in perception of whether a company’s plan will complete the journey to new drug approvals ( and how long it’ll take). Especially for small to moderately grand, truly ingenious biotech companies, a few facets determine failure or success COVID-19 put a damper on these operations and threw the industry into a precarious position.
Share it on social networks: Tweet Share
SMEBOOK is reinventing the management of tech companies’ assets by providing a matchmaking algorithm capable of recommending partnerships according to needs and interests.